In addition, BL6 decreased tau phosphorylation and attenuated synaptophysin reduction in the hippocampus of icv-STZ mice (Figure 10), suggesting partial alleviation of the AD pathology, although further biochemical, anatomical, and behavioral studies, including Aβ plaque analysis, using both male and female mice, will be necessary to evaluate the efficacy of BL6 to mitigate AD pathology and behavior. This evidence concerns the gene MAPT and Alzheimer disease.